TopFunds

Boston Scientific Corporation

NYSE: BSX

Stock price

44.39 USD

(+0%) TODAY

Medical - Devices
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
(0.2)
0.3
0.1
1.2
3.3
(0.1)
0.7
0.4
1.1
1.3
1.9
-
02Free cash flow per share
0.3
0.4
0.8
-
1
0.8
0.9
0.6
1.2
1.8
2.4
25%
03Dividends per share
-
-
-
-
-
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
(34.2)%
5.3%
7.9%
1.8%
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
7,477
8,386
9,048
9,823
10,735
9,913
11,888
12,682
14,240
16,747
20,074
10.4%
06% Change
-
-
-
-
-
-
-
-
-
-
-
10.4%
07Cost of revenue
(2,835)
(3,043)
(3,177)
(3,346)
(3,856)
(4,337)
(4,427)
(4,968)
(5,409)
(6,480)
(6,221)
8.2%
08Gross profit
4,564
5,343
5,871
6,477
6,879
5,576
7,461
7,714
8,831
10,267
13,853
11.7%
09% Margin
61%
63.7%
64.9%
65.9%
64.1%
56.3%
62.8%
60.8%
62%
61.3%
69%
62.9% A
10Operating expenses
(3,774)
(4,107)
(4,346)
(4,740)
(5,167)
(4,975)
(5,539)
(5,890)
(6,650)
(7,632)
(9,882)
10.1%
11% of Revenue
(50.5)%
(49)%
(48)%
(48.3)%
(48.1)%
(50.2)%
(46.6)%
(46.4)%
(46.7)%
(45.6)%
(49.2)%
(48.1)% A
12Operating Income
790
1,236
1,525
1,737
1,712
601
1,922
1,824
2,181
2,635
3,971
17.5%
13Income tax expense
(411)
(170)
(828)
(249)
(4,013)
(2)
(36)
(443)
(393)
(436)
(493)
-
14Net Income
(239)
347
104
1,671
4,700
(82)
1,040
698
1,593
1,854
2,886
-
15% Margin
(3.2)%
4.1%
1.2%
17%
43.8%
(0.8)%
8.8%
5.5%
11.2%
11.1%
14.4%
10.3% A
16Shares Outstanding
1,341
1,377
1,393
1,401
1,411
1,417
1,434
1,440
1,464
1,486
1,495
1.1%
17EPS Basic
(0.2)
0.3
0.1
1.2
3.4
(0.1)
0.7
0.4
1.1
1.3
2
-
18EPS Diluted
(0.2)
0.3
0.1
1.2
3.3
(0.1)
0.7
0.4
1.1
1.3
1.9
-
19EBITDA
360
1,226
2,007
2,585
2,211
1,512
2,518
2,741
3,453
3,938
5,102
30.4%
% Margin
4.8%
14.6%
22.2%
26.3%
20.6%
15.3%
21.2%
21.6%
24.3%
23.5%
25.4%
20% A
20Net Interest Income (expense)
(236)
(229)
(225)
(266)
(483)
(465)
(345)
(454)
(250)
(280)
(349)
4%
21Net Debt / EBITDA
14.9
4.3
2.7
2.7
4.5
5.2
3
3
2.5
2.7
2
4.3 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
319
196
188
146
217
1,734
1,925
928
865
414
2,045
20.4%
23Short-term investments
-
-
-
-
-
-
-
-
-
-
-
-
24Accounts receivable
1,275
1,472
1,548
1,608
1,828
1,531
1,778
1,970
2,228
2,558
2,926
8.7%
25Other current assets
918
616
1,008
1,083
1,075
2,078
1,004
995
937
1,138
879
(0.4)%
26Inventory
1,016
955
1,078
1,166
1,579
1,351
1,610
1,867
2,484
2,810
2,944
11.2%
27Total Current Assets
3,471
3,239
3,822
4,003
4,699
6,694
6,317
5,760
6,514
6,920
8,794
9.7%
Non-Current Assets
28Net property, plant & equipment
1,490
1,630
1,696
1,782
2,415
2,541
2,686
2,831
3,298
3,744
4,501
11.7%
29Long-term investments
(496)
(75)
(191)
(328)
458
918
412
407
413
555
842
-
30Other non-current assets
13,668
13,302
13,714
15,543
22,993
20,622
22,813
23,472
24,911
28,177
29,536
8%
31Total Non-Current Assets
14,662
14,857
15,219
16,997
25,866
24,081
25,911
26,710
28,622
32,476
34,879
9.1%
Total Assets
18,133
18,096
19,041
20,998
30,565
30,778
32,230
32,470
35,136
39,395
43,673
9.2%
LIABILITIES
Current Liabilities
32Accounts payable
209
447
530
349
542
513
794
862
942
960
1,144
18.5%
33Short-term debt
3
64
1,801
2,253
1,416
13
261
20
531
1,778
389
62.7%
34Other current liabilities
2,218
3,076
3,323
2,658
2,908
3,155
3,219
2,921
3,460
3,661
3,906
5.8%
35Total Current Liabilities
2,430
3,587
5,654
5,260
4,866
3,681
4,274
3,803
4,933
6,399
5,439
8.4%
Non-Current Liabilities
36Long-term debt
5,674
5,421
3,816
4,803
8,868
9,526
9,193
9,262
8,961
9,369
12,029
7.8%
37Other non-current liabilities
3,709
2,355
2,560
2,210
2,954
2,244
2,140
1,831
1,712
1,624
1,733
(7.3)%
38Total Non-Current Liabilities
9,383
7,776
6,376
7,013
11,822
11,770
11,333
11,093
10,673
10,993
13,762
3.9%
39Total Liabilities
11,813
11,363
12,030
12,273
16,688
15,451
15,607
14,896
15,606
17,392
19,201
5%
SHAREHOLDERS` EQUITY
40Common stock
16
19
16
16
16
17
17
17
17
17
17
0.6%
41Retained earnings / (deficit)
(8,927)
(8,583)
(8,390)
(6,953)
(2,253)
(2,378)
(1,392)
(750)
819
2,673
5,571
-
42Accumulated other comprehensive income / (loss)
88
1
(59)
33
270
207
263
269
49
275
(610)
-
43Noncontrolling interests
-
-
-
-
-
-
-
-
248
233
239
-
44Total shareholders' equity
6,320
6,733
7,011
8,725
13,877
15,327
16,623
17,574
19,530
22,003
24,472
14.5%
45Total Liabilities and shareholders' Equity
18,133
18,096
19,041
20,998
30,565
30,778
32,230
32,470
35,136
39,395
43,673
9.2%
46Total Debt
5,677
5,484
5,578
7,030
10,277
9,539
9,451
9,282
9,492
11,147
12,418
8.1%
47Net Debt
5,358
5,288
5,390
6,884
10,060
7,805
7,526
8,354
8,627
10,733
10,373
6.8%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
(239)
347
104
1,671
4,700
(82)
1,040
698
1,593
1,854
2,886
-
49Depreciation & amortization
769
815
844
894
1,011
1,123
1,093
1,136
1,196
1,269
1,368
5.9%
50Share-based compensation expense
107
116
127
140
157
170
194
220
233
266
299
10.8%
51Changes in working capital and other assets
(37)
(306)
351
(2,395)
(4,032)
297
(456)
(528)
(519)
46
(19)
(6.5)%
52Net cash flows from operating activities
600
972
1,426
310
1,836
1,508
1,871
1,526
2,503
3,435
4,534
22.4%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(247)
(376)
(319)
(316)
(461)
(376)
(554)
(612)
(711)
(790)
(876)
13.5%
54Purchases of investments / marketable securities
(266)
(132)
(131)
(172)
(348)
(146)
96
(24)
-
-
-
-
55Proceeds from maturities of marketable securities
61
-
131
14
59
12
294
56
-
-
-
-
56Other investing activities
(1,734)
(379)
(691)
(1,447)
(4,291)
99
(1,433)
(1,431)
(1,863)
(4,897)
(1,764)
0.2%
57Net cash flows from investing activities
(2,186)
(887)
(1,010)
(1,921)
(5,041)
(411)
(1,597)
(2,011)
(2,574)
(5,687)
(2,640)
1.9%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
114
111
85
101
123
440
110
136
182
230
282
9.5%
59Dividends paid, net
-
-
-
-
-
(28)
(55)
(55)
(28)
-
-
-
60Debt issuance (repayments), net
1,385
(190)
123
1,405
2,794
(999)
-
(165)
(4)
1,827
(491)
-
61Other financing activities
(177)
(127)
(98)
(74)
56
880
(150)
(464)
(145)
(243)
(186)
0.5%
62Net cash flows from financing activities
1,322
(206)
110
1,432
2,973
293
(95)
(548)
5
1,814
(395)
-
63Increase (decrease) in cash and cash equivalents
(268)
(123)
530
(190)
(222)
1,388
171
(1,042)
(82)
(449)
1,541
-
64Cash and equivalents, ending balance
319
196
1,017
829
607
1,995
2,168
1,126
995
606
2,147
21%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
353
596
1,107
(6)
1,375
1,132
1,317
914
1,792
2,645
3,658
26.3%

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
2025202420232022202120202019201820172016

Boston Scientific Corporation (BSX) financial statements and performance

Explore Boston Scientific Corporation (BSX) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.